F11 and atrial fibrillation: Among patients with multiple comorbidities, including renal dysfunction, cancer, or atrial fibrillation, FXI inhibitors have maintained a favorable safety profile, with low rates of major bleeding and efficacy broadly comparable to standard anticoagulant therapy [65,66,69].